Effect-site Concentration of Remifentanil for Double-lumen Tubes Intubation: Airtraq VS Macintosh Laryngoscope

Effect-site Concentration of Remifentanil for Inhibiting Cardiovascular Responses to Double-lumen Tube Intubation With Airtraq Videolaryngoscopy: a Comparative Study With Macintosh Laryngoscopy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03653910

Enrollment

Registered

2018-08-31

Start date

2018-09-03

Completion date

2019-05-17

Last updated

2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodynamic Instability, Intubation Complication

Keywords

double-lumen tube intubation, remifentanil, target controlled infusion

Brief summary

The 50% effective concentration of remifentanil by target controlled infusion was not determined for inhibiting the haemodynamic response during double-lumen tube (DLT) intubation. Previous study showed that Airtraq videolaryngoscope provided more stable haemodynamics than Macintosh for double-lumen tube intubation. In this study, the investigators will compare the 50% effective concentration of remifentanil between Airtraq videolaryngoscope and Macintosh laryngoscope for inhibiting haemodynamic responses during DLT intubation.

Detailed description

Dixon up-and-down method was used to determine 50% effective concentration of remifentanil by target controlled infusion for inhibiting the haemodynamic responses during DLT intubation with Airtraq videolaryngoscope or Macintosh laryngoscope.

Interventions

DEVICEAirtraq

Airtraq is a kind of videolaryngoscope for intubation

DEVICEMacintosh

Macintosh is a traditional laryngoscope for intubation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

s: 1. American Society of Anesthesiologists physical status of I-II 2. Patients aged 18-65 years 3. BMI 18-35 kg/m2 4. Elective pulmonary surgery under general anesthesia to double-lumen tubes intubation 5. Mallampati classifications Ⅰ-Ⅱ

Exclusion criteria

s: 1. Emergency operation 2. Anticipated difficult airway or history of intubation difficulties 3. Be allergic to any of the drugs used in the experiment, or have a history of drug allergy 4. Preoperative use of analgesic, sedative and other drugs 5. Uncontrolled hypertension and heart disease 6. Have a history of heavy smoking and alcohol abuse, serious drug abuse, and severe systemic infections 7. There are severe mental and nervous system symptoms, and patients cannot cooperate with the study, such as language comprehension disorder, mental illness, etc 8. Other clinical trials were conducted within 3 months prior to inclusion in the study

Design outcomes

Primary

Measure	Time frame	Description
Remifentanil TCI effect site concentration	through study completion, an average of 20 min	preestablish remifentanil TCI effect site concentration(ng/ml)

Secondary

Measure	Time frame	Description
mean arterial pressure	at entering the operation room(T1), at immediately before DLT intubation(T2), at immediately after DLT intubtion(T3), at 1 minute(T4)/2 minutes (T5)/3 minutes(T6) after DLT intubation	mean arterial pressure in mmHg
heart rate	at entering the operation room(T1), at immediately before DLT intubation(T2), at immediately after DLT intubtion(T3), at 1 minute(T4)/2 minutes (T5)/3 minutes(T6) after DLT intubation	heart rate in bpm
Narcotrend index	at entering the operation room(T1), at immediately before DLT intubation(T2), at immediately after DLT intubtion(T3), at 1 minute(T4)/2 minutes (T5)/3 minutes(T6) after DLT intubation	Narcotrend index in Arabic numerals

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026